Bonnet F, Burty C, Lewden C, et al; Agence Nationale de Recherches sur le Sida et les Hépatites Virales EN19 Mortalité Study Group; Mortavic Study Group. Changes in cancer mortality among HIV-infected patients: The Mortalité 2005 Survey. Clin Infect Dis. 2009;48:633-639.

Centers for Disease Control and Prevention. 1993 Revised Classification System for HIV Infection and Expanded Case Definitions for AIDS among Adolescents and Adults. MMWR. 1992;41(RR-17). Accessed at on July 22, 2014.

Centers for Disease Control and Prevention. HIV/AIDS: Statistics Overview. Accessed at on July 21, 2014.

Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10:412-426.

Clifford GM, Polesel J, Rickenbach M, et al; Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.

Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin’s lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma. 2006;47:1822-1829.

Diamond C, Taylor TH, Im T, et al. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin’s lymphoma. Curr HIV Res. 2006;4:375-378.

Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2010;54:78-84.

Franceschi S, Lise M, Clifford GM, et al; Swiss HIV Cohort Study. Changing patterns of cancer incidence in the early- and late-HAART periods: The Swiss HIV Cohort Study. Br J Cancer. 2010;103:416-422.

Gopal S, Achenbach CJ, Yanik EL, et al. Moving forward in HIV-associated cancer. J Clin Oncol. 2014;32:876-880.

Guiguet M, Boué F, Cadranel J, et al; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): A prospective cohort study. Lancet Oncol. 2009;10:1152-1159.

Marrazzo JM, del Rio C, Holtgrave DR, et al. HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society–USA Panel. JAMA. 2014;312:390-409.

Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551-2559.

Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105:350-360.

Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS. 2007;21:1957-1963.

Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17:1787-1793.

Thompson MA, Aberg JA, Cahn P, Montaner JS, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-333.

UNAIDS (Joint United Nations Global AIDS Programme). Global report: UNAIDS report on the global AIDS epidemic 2013. Accessed at on July 23, 2014.

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master's-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Last Medical Review: July 25, 2014 Last Revised: July 25, 2014

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.